Merck & Co Inc
NYSE:MRK
Operating Margin
Merck & Co Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Merck & Co Inc
NYSE:MRK
|
237.8B USD |
36%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
771.5B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
391.5B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
242.9B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
194.9B CHF |
32%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
158.2B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.1B USD |
25%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
132.4B EUR |
21%
|
Merck & Co Inc
Glance View
Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Merck & Co Inc's most recent financial statements, the company has Operating Margin of 36.5%.
You don't have any saved screeners yet